Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population.
Nelson JW, Hatch EE, Webster TF. · 2010
Read Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. by Nelson JW, Hatch EE, Webster TF. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2831917.txt.
Introduction
Nelson, Hatch, and Webster checked in 2010 whether stain-proofing chemicals in blood track with cholesterol, weight, and insulin resistance in the general United States population. The chemicals, called PFCs, coat packaging and fabrics and persist in the body for years. Data came from the national NHANES survey of 2003 to 2004, covering ages twelve to eighty.
Three of the four chemicals studied rose alongside total cholesterol. People in the top quarter for one chemical, PFOS, carried total cholesterol about thirteen points higher than those in the bottom quarter, a gap measured in milligrams per deciliter. The fourth chemical ran the other way. Links with body size and insulin resistance were weak and patchy, so the authors call the work exploratory.
Catalog record
| CREATOR | Nelson JW, Hatch EE, Webster TF. |
|---|---|
| YEAR | 2010 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| LICENSE | CC0 1.0 Universal |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Exposure to Polyfluoroalkyl Chemicals and Cholesterol, Body Weight, and Insulin Resistance in the General U.S. Population By Jessica W. Nelson, Elizabeth E. Hatch, Thomas F. Webster Published in: Environmental Health Perspectives DOI: 10.1289/ehp.0901165 ABSTRACT Background Polyfluoroalkyl chemicals (PFCs) are used commonly in commercial applications and are detected in humans and the environment worldwide. Concern has been raised that they may disrupt lipid and weight regulation. Objectives We investigated the relationship between PFC serum concentrations and lipid and weight outcomes in a large publicly available data set. Methods We analyzed data from the 2003–2004 National Health and Nutrition Examination Survey (NHANES) for participants 12–80 years of age. Using linear regression to control for covariates, we studied the association between serum concentrations of perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) and measures of cholesterol, body size, and insulin resistance. Results We observed a positive association between concentrations of PFOS, PFOA, and PFNA and total and non-high-density cholesterol. We found the opposite for PFHxS. Those in the highest quartile of PFOS exposure had total cholesterol levels 13.4 mg/dL [95% confidence interval (CI), 3.8–23.0] higher than those in the lowest quartile. For PFOA, PFNA, and PFHxS, effect estimates were 9.8 (95% CI, −0.2 to 19.7), 13.9 (95% CI, 1.9–25.9), and −7.0 (95% CI, −13.2 to −0.8), respectively. A similar pattern emerged when exposures were modeled continuously. We saw little evidence of a consistent association with body size or insulin resistance. Conclusions This exploratory cross-sectional study is consistent with other epidemiologic studies in finding a positive association between PFOS and PFOA and cholesterol, despite much lower exposures in NHANES. Results for PFNA and PFHxS are novel, emphasizing the need to study PFCs other than PFOS and PFOA. Polyfluoroalkyl chemicals (PFCs) are a class of highly stable compounds used widely in commercial and industrial applications as surfactants, paper and textile coatings, and food packaging (Calafat et al. 2007). Numerous chemicals belong to this class, including the products used industrially, by-products of manufacturing, and degradation products. They are composed of a fluorinated carbon backbone of varying length terminated by a carboxylate or sulfonate functional group. This amphipathic structure provides the properties of water and oil repellency and stain resistance (Conder et al. 2008). The perfluorinated carboxylates include perfluorooctanoic acid (PFOA) and perfluorononanoic acid (PFNA), and the perfluorinated sulfonates include perfluorooctane sulfonic acid (PFOS) and perfluorohexane sulfonic acid (PFHxS). Biomonitoring studies have documented human exposure to PFCs, both in occupationally exposed cohorts (Costa et al. 2009; Olsen and Zobel 2007; Sakr et al. 2007a) and in the general population (Apelberg et al. 2007; Calafat et al. 2007; Fei et al. 2007). Although the major sources of human exposure are poorly known, possibilities include diet (either directly from food or migration from food packaging), drinking water, and house dust (reviewed in Lau et al. 2007). Once taken into the human body, PFCs are slowly eliminated and are not known to undergo biotransformation (Lau et al. 2007). They bioaccumulate, but not in lipid as do many other persistent organic pollutants. Instead, they bind to proteins in the liver and serum (Conder et al. 2008). Mean serum half-lives in humans are estimated as 5.4 years for PFOS and 3.8 years for PFOA (Olsen et al. 2007). Shorter-chain compounds are generally assumed to have shorter half-lives, although PFHxS is an exception, with an estimated mean half-life of 8.5 years (Olsen et al. 2007). The half-life for PFNA in humans has not been estimated. Various adverse health effects have been observed in animal studies of PFOS and PFOA, including tumors in certain organs and developmental delays (Biegel et al. 2001; White et al. 2007). The structural resemblance of PFCs to fatty acids and the discovery that they bind to peroxisome proliferator-activated receptors (PPARs), nuclear receptors that play a key role in lipid metabolism and adipogenesis, have raised the concern that PFCs may disrupt lipid and weight regulation. Indeed, among the early reported health effects in animal studies that administered high PFC doses was hypolipidemia (Seacat et al. 2002). However, several studies in humans suggest that exposure to PFOA, and possibly to PFOS, may be associated with increased cholesterol in humans (C8 Science Panel 2008; Costa et al. 2009; Sakr et al. 2007a). The evidence for an association between PFC exposure and body size and insulin resistance is much weaker (Lin et al. 2009). The rising prevalence of the metabolic syndrome, which includes obesity, dyslipidemia, and insulin resistance, is of increasing public health concern in the United States and globally and is linked closely with coronary heart disease and related disorders (Ramos and Olden 2008). Although changes in diet and lifestyle are undoubtedly important factors in this trend, there is growing interest in the hypothesis that endocrine-disrupting chemicals may be playing a role (Grun and Blumberg 2009). This exploratory, cross-sectional epidemiologic study investigated the relationship between exposure to four PFCs, including two compounds that have been little studied in humans, and cholesterol levels, obesity, and insulin resistance. MATERIALS AND METHODS Study population The National Health and Nutrition Examination Survey (NHANES) is an ongoing survey of the civilian noninstitutionalized U.S. population conducted by the Centers for Disease Control and Prevention (CDC) that gathers data on dietary and health factors. Participants are selected using a complex multistage probability sampling design and come to a mobile examination center for a physical examination and to provide blood and urine samples. Various questionnaires are administered by trained interviewers (CDC 2009). The survey also includes biomonitoring for different environmental chemicals, including PFCs, of a random one-third subsample of participants by the National Center for Environmental Health (NCEH). NHANES obtained informed consent from all participants. PFC concentrations PFCs were measured in serum of participants ≥ 12 years of age by the NCEH using automated solid-phase extraction coupled to isotope dilution/high-performance liquid chromatography/tandem mass spectrometry; details of laboratory methods are available elsewhere (Calafat et al. 2007). Our study examined the four PFCs detected in > 98% of people: PFOS, PFOA, PFHxS, and PFNA. The other eight PFCs measured were detected in < 28% of people. Values below the limit of detection (LOD) were reported by NHANES as the LOD divided by the square root of 2. Outcomes Several cholesterol measures are commonly used in clinical and epidemiologic studies. Cholesterol is carried in plasma within different lipoproteins, including low-density lipoproteins (LDLs) and very low-density lipoproteins (VLDLs) which carry cholesterol to peripheral tissues and are considered “bad” cholesterol, and high-density lipoproteins (HDLs) which transport cholesterol back to the liver for excretion and are considered “good” cholesterol. LDL carries around 70% of total plasma cholesterol, and HDL 20−30% (Tietz et al. 2006). Total cholesterol (TC) is the sum of the cholesterol content of LDL, HDL, and VLDL. The non-HDL cholesterol fraction, which includes LDL and VLDL cholesterol, has been shown to be a better predictor of risk of coronary heart disease than LDL alone (Liu et al. 2006). We studied TC, HDL, non-HDL, and LDL. TC and HDL were measured by NHANES directly in serum of all participants; TC was measured enzymatically through coupled reactions that hydrolyze cholesteryl esters, and HDL after the precipitation of apolipoprotein B lipoproteins with a blocking agent (CDC 2007b). We calculated non-HDL